Transplantation efficacy of autologous bone marrow mesenchymal stem cells combined with atorvastatin for acute myocardial infarction (TEAM-AMI): rationale and design of a randomized, double-blind, placebo-controlled, multi-center, Phase II TEAM-AMI trial

• Published in: Regenerative medicine 2019-12, Vol.14 (12), p.1077-1087
• Main Authors: Xu, Jun-Yan, Qian, Hai-Yan, Huang, Pei-Sen, Xu, Jun, Xiong, Yu-Yan, Jiang, Wen-Yang, Xu, Yi, Leng, Wen-Xiu, Li, Xiang-Dong, Chen, Gui-Hao, Tang, Rui-Jie, Huang, Cun-Rong, Hu, Meng-Jin, Jin, Chen, Wu, Yuan, Zhang, Jun, Qian, Jie, Xu, Bo, Zhao, Shi-Hua, Lu, Min-Jie, Shen, Rui, Fang, Wei, Wu, Wei-Chun, Chen, Xi, Wang, Yang, Li, Wei, Lu, Xiang-Feng, Jiang, Xi-Feng, Ma, Chun-Cheng, Li, Jian-Wen, Geng, Yong-Jian, Qiao, Shu-Bin, Gao, Run-Lin, Yang, Yue-Jin
• Format: Article
• Language: English
• Subjects: acute myocardial infarction; autologous bone marrow mesenchymal stem cell; cardiac function; cardiac micro-environment; intensive atorvastatin; stem cell therapy
• ISSN: 1746-0751; 1746-076X
• DOI: 10.2217/rme-2019-0024

To determine the efficacy and safety of intracoronary infusion of autologous bone marrow mesenchymal stem cells (MSC ) in combination with intensive atorvastatin (ATV) treatment for patients with anterior ST-segment elevation myocardial infarction-elevation myocardial infarction. The trial enrolls a total of 100 patients with anterior ST-elevation myocardial infarction. The subjects are randomly assigned (1:1:1:1) to receive routine ATV (20 mg/d) with placebo or MSCs and intensive ATV (80 mg/d) with placebo or MSCs . The primary end point is the absolute change of left ventricular ejection fraction within 12 months. The secondary end points include parameters in cardiac function, remodeling and regeneration, quality of life, biomarkers and clinical outcomes. The trial will implicate the essential of cardiac micro-environment improvement (‘fertilizing’) for cell-based therapy. NCT03047772.